Dyadic International (DYAI) said Wednesday it has entered into an agreement with a global food ingredients company to come up with animal-free products...
Dyadic International (DYAI) said Wednesday its licensee Epygen Biotech received funding from the Indian government to develop a low-cost COVID-19 vaccine...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Dyadic International (DYAI) and Phibro Animal Health (PAHC) said Thursday they entered into a licensing deal to develop a cell-based poultry vaccine...
| Address | 140 Intracoastal Pointe Drive Jupiter, Florida 33477-5094 |
| Phone | +1.561.743.8333 |
| Number of Employees | 8 |
| Recent SEC Filing | 06/14/2022 4 |
| President, Chief Executive Officer & Director | Mark A. Emalfarb |
| Chief Financial Officer | Ping W. Rawson |
| Vice President-Research & Business Development | Ronen Tchelet |
| MD-Business Development & Licensing | Matthew S. Jones |
| Price Open | $3.04 |
| Previous Close | $3.05 |
| 52 Week Range | $1.74 - 6.89 |
| Market Capitalization | $85.9 M |
| Shares Outstanding | 28.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.44 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.3 M |
| Net Profit Margin | -473.31% |
| Return on Equity | -61.45% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
